A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment

Significant advances have been made in the development of Adverse Outcome Pathways (AOPs) over the last decade, mainly focused on the toxicity mechanisms of chemicals. These AOPs, although relevant to manufactured nanomaterials (MNs), do not currently capture the reported roles of size-associated properties of MNs on toxicity. Moreover, some AOs of relevance to airborne exposures to MNs such as lung inflammation and fibrosis shown in animal studies may not be targeted in routine regulatory decision making. The primary objective of the present study was to establish an approach to advance the development of AOPs of relevance to MNs using existing, publicly available, nanotoxicology literature. A systematic methodology was created for curating, organizing and applying the available literature for identifying key events (KEs). Using a case study approach, the study applied the available literature to build the biological plausibility for 'tissue injury', a KE of regulatory relevance to MNs. The results of the analysis reveal the various endpoints, assays and specific biological markers used for assessing and reporting tissue injury. The study elaborates on the limitations and opportunities of the current nanotoxicology literature and provides recommendations for the future reporting of nanotoxicology results that will expedite not only the development of AOPs for MNs but also aid in application of existing data for decision making.

Automated summary

Significant progress has been made in the development of Adverse Outcome Pathways (AOPs) focusing on the toxicity mechanisms of chemicals, but there is a lack of consideration for the size-associated properties of manufactured nanomaterials (MNs) in current AOPs. By utilizing existing nanotoxicology literature, this study established a systematic methodology for identifying key events (KEs) relevant to MNs and addressed the limitations and opportunities in the field. Recommendations were provided for future reporting of nanotoxicology results to expedite the development of AOPs for MNs and aid in regulatory decision making.